Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP19 | DOI: 10.1530/endoabs.90.EP19

1Baskent University Faculty of Medicine, Endocrinology and Metabolism, Adana, Turkey; 2Mehmet Ali Aydınlar University Faculty of Medicine, Endocrinology and Metabolism, Istanbul, Turkey; 3Akdeniz University Faculty of Medicine, Endocrinology and Metabolism, Antalya, Turkey; 4Cukurova University Faculty of Medicine, Endocrinology and Metabolism, Adana, Turkey; 5University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Endocrinology and Metabolism, Istanbul, Turkey; 6Erciyes University Faculty of Medicine, Endocrinology and Metabolism, Kayseri, Turkey; 7Istanbul University Faculty of Medicine, Endocrinology and Metabolism, Istanbul, Turkey; 8Ankara University Faculty of Medicine, Endocrinology and Metabolism, Ankara, Turkey; 9Canakkale 18 Mart University Faculty of Medicine, Endocrinology and Metabolism, Canakkale, Turkey; 10Ege University Faculty of Medicine, Endocrinology and Metabolism, Izmir, Turkey; 11Eskisehir Osmangazi University Faculty of Medicine, Endocrinology and Metabolism, Eskisehir, Turkey; 12Uludag University Faculty of Medicine, Endocrinology and Metabolism, Bursa, Turkey; 13University of Health Sciences, Adana Training and Research Hospital, Endocrinology and Metabolism, Adana, Turkey; 14K. Maras Sutcu Imam University Faculty of Medicine, Endocrinology and Metabolism, K. Maras, Turkey; 15University of Health Sciences, Antalya Training and Research Hospital, Endocrinology and Metabolism, Antalya, Turkey; 16Inonu University Faculty of Medicine, Endocrinology and Metabolism, Malatya, Turkey; 17Istanbul Medeniyet University Faculty of Medicine, Endocrinology and Metabolism, Istanbul, Turkey; 18Pamukkale University Faculty of Medicine, Endocrinology and Metabolism, Denizli, Turkey; 19University of Health Sciences, Ankara Training and Research Hospital, Endocrinology and Metabolism, Ankara, Turkey


Introduction: Congenital adrenal hyperplasia (CAH) is a group of autosomal recessively inherited disorders that are characterised by inactivating mutations at various steps of adrenal steroidogenic pathways causing defective cortisol biosynthesis. 21-Hydroxylase enzyme deficiency (21-OHd) constitutes more than 95% of all CAH cases.

Material & Methods: Medical records of patients with all forms of CAH from 19 adult endocrinology clinics located at six different geographical regions of Turkey are evaluated in this multicentre study. Findings of 21-OHd CAH cases (n=181) eligible for analysis are given.

Findings: There were 101 (55.8%) classical and 80 (44.2%) nonclassical 21-OHd CAH cases. General features of cases can be found in Table. More patients in nonclassical CAH group were married and had children. Reconstructive genital surgery was performed in 54 (78.3%) of classical CAH females and 42 (77.8%) of them had no children. Data about genetic analysis were reached in 120 cases (57 classical CAH, 63 NCAH). V281L mutation was detected in 21 (33.3%) of 21-OHd NCAH patients.

21-OHd CAH (n=181)Classical CAH (n=101)Non-Classical CAH (n=80)P
(55.8%)(44.2%)
Gender (n, %)
Male31 (30.7)8 (10)0.002
Female 69(68.3)72 (90)
Female to male 1 (1.0)
Age at diagnosis (years)4.99 ±9.8620.02 ± 12.670.02
Time on follow-up (years)17.49±9.43 (n=97)7.23±8.71 (n=71)0.176
Education Level (n,%)
Unknown17 (16.8)12 (15)0.375
Preliminary School and below10 (10)10 (12.6)
High School46 (45.5)30 (37.5)
University degree and above28 (27.7)28 (35.1)
Diagnosing Physician (n=180) (n,%)
General or Pediatric Endocrinologist83 (82.2)20 (25.3)0.000
Internal Medicine Specialist/ Adult Endocrinologist8 (7.9)54 (68.4)
Gynecologist or Others10 (9.9)5 (6.3)
Consanguinity between parents (n, %)
YES54 (53.5)14 (17.5)0.000
NO36 (35.6)42 (52.5)
Unknown11 (10.9)24 (30)
Marital Status (n, %)
Single65 (64.4)41 (51.2)0.003
Married21 (20.8)33 (41.3)
Divorced0 (0.0)2 (2.5)
Unknown 15 (14.9)4 (5.0)
Having children (n, %)
YES6 (5.9)29 (36.3)0.000
NO77 (76.2)40 (50.0)
Unknown18 (17.8) 11 (13.8)
Used Glucocorticoid name(n, %)(n=101)(n=77)
Dexamethasone21 (20.8)8 (10.4)0.000
Methylprednisolone5 (5.0)0 (0.0)
Prednisolone23 (22.8)9 (11.7)
Hydrocortisone43 (42.6)12 (15.6)
Dexamethasone + Methylprednisolone1 (1.0)0 (0.0)
Dexamethasone + Hydrocortisone3 (3.0)0 (0.0)
Unknown-None5 (5.0)48 (62.3)

Discussion: Interpretation of findings of this study will improve our knowledge about CAH and will inevitably result in better health service.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors